Originally published March 6.
Researchers conducting a prospective analysis of the psychological and behavioral impact of personal genomics data announced this week that they are ready to send out surveys to study participants.
By Andrea Anderson
NEW YORK (GenomeWeb News) – A research team from the Netherlands and the US has sequenced the genome of a woman who lived to be 115 years old and remained exceptionally healthy for most of her life.
The Scripps Translational Science Institute will provide solid human tumor samples to the effort, which is building a library of primary human tumors in the hopes of developing highly targeted cancer therapies.
Quest, which plans to acquire Celera by the end of the month, could provide the financial backing to conduct prospective studies for the KIF6 test, or it could decide to scrap the KIF6 program altogether.
Next-generation sequencing "is emerging more and more as an approach to supplement how patients [with cancer] are treated, so we wanted to try and iron out the technical aspects of it … so we can really feel confident that as a methodology, it works."
Focus and Quest are collaborating with clinical scientists from Scripps Translational Science Institute and Scripps Health to develop the test, which could eventually help clinicians personalize treatment with Plavix based on a patient's CYP2C19 genotype in less than an hour.
At the Future of Genomics Medicine conference hosted earlier this month by the Scripps Translational Research Institute, several speakers discussed the rapid progress they have made in developing genomic tests to detect disease and guide treatment, as well as the hurdles to commercialization.